Kazia Therapeutics (KZIA) Cash from Financing Activities (2016)

Kazia Therapeutics' (KZIA) quarterly Cash from Financing Activities came in at -$13249.3 in Q4 2016.

Kazia Therapeutics (KZIA) Cash from Financing Activities (2016) Analysis & Trends

Kazia Therapeutics (KZIA) has 1 years of Cash from Financing Activities data on file, last reported at -$13249.3 in Q4 2016.

Quarterly Cash from Financing Activities changed N/A year-over-year to -$13249.3 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $19.4 million (changed N/A YoY) and the FY2025 annual result came in at $10.2 million, up 159.5% from the prior year.
Cash from Financing Activities was little changed at -$13249.3 in Q4 2016.
In the past five years, Cash from Financing Activities ranged from a high of -$13249.3 in Q4 2016 to a low of -$13249.3 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Financing Activities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-426.70 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-1.22 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.42 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-6.05 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-207,909.22
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-273.15 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	36.24 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	27.18 Mn
10	Kazia Therapeutics	4.22 Bn	4.22 Bn	-	-

Download Data

Date	Value
Dec 31, 2016	-13,249.30
Dec 31, 2016	-13,249.30